Literature DB >> 30662662

LncRNA PICART1 suppressed non-small cell lung cancer cells proliferation and invasion by targeting AKT1 signaling pathway.

Chunling Zhang1, Chuanzhi Su2, Qi Song1, Fushi Dong1, Shihuan Yu1, Jianmin Huo1.   

Abstract

LncRNAs play significant roles in various cell biological processes. In the present study, we demonstrated that PICART1 expression was down-regulated in non-small cell lung cancer (NSCLC) tissues. Lower expression level of PICART1 was associated with advanced stage. In addition, PICART1 expression was down-regulated in NSCLC cell lines. Overexpression of PICART1 inhibited NSCLC cell growth and induced cell cycle arrest at G2/M phase. Elevated expression of PICART1 suppressed NSCLC cell colony formation and cell invasion. Ectopic expression of PICART1 promoted the expression of epithelial marker E-cadherin while suppressed the mesenchymal marker expression such as N-cadherin and Snail and Vimentin. Furthermore, PICART1 overexpression suppressed AKT phosphorylation and c-Myc expression while inhibited the p21 expression in NSCLC cell. AKT phosphorylation was involved in PICART1 mediated suppression of cell growth and invasion. These results suggested that overexpression of PICART1 suppressed cell growth and invasion partly through regulating AKT signaling pathway in NSCLC.

Entities:  

Keywords:  AKT; Non-small cell lung cancer; PICART1; long non-coding RNAs

Year:  2018        PMID: 30662662      PMCID: PMC6325487     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  14 in total

1.  HNF1A-Induced lncRNA HCG18 Facilitates Gastric Cancer Progression by Upregulating DNAJB12 via miR-152-3p.

Authors:  Pei Ma; Lianhai Li; Fu Liu; Qi Zhao
Journal:  Onco Targets Ther       Date:  2020-08-03       Impact factor: 4.147

2.  Long Noncoding RNA TFAP2A-AS1 Suppressed Hepatitis B Virus Replication by Modulating miR-933/HDAC11.

Authors:  Yu Cheng; Weiwu Shi; Xudong Cui; Lei Sun; Yi Nan; Hong Yao; Jian Fan; LiYing Zhu; Lei Yu
Journal:  Dis Markers       Date:  2022-04-18       Impact factor: 3.464

3.  Silencing of SETD6 inhibits the tumorigenesis of oral squamous cell carcinoma by inhibiting methylation of PAK4 and RelA.

Authors:  Wentao Huang; Hongjing Liu; Tianzhu Lv
Journal:  Histol Histopathol       Date:  2021-03-12       Impact factor: 2.303

4.  LncRNA BCRT1 facilitates osteosarcoma progression via regulating miR-1303/FGF7 axis.

Authors:  Gang Han; Quanyi Guo; Ning Ma; Wenzhi Bi; Meng Xu; Jinpeng Jia; Wei Wang
Journal:  Aging (Albany NY)       Date:  2021-06-08       Impact factor: 5.682

5.  Long noncoding RNA HOXA-AS2 promotes non-small cell lung cancer progression by regulating miR-520a-3p.

Authors:  Yunpeng Liu; Xingyu Lin; Shiyao Zhou; Peng Zhang; Guoguang Shao; Zhiguang Yang
Journal:  Biosci Rep       Date:  2019-05-31       Impact factor: 3.976

6.  LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.

Authors:  Wenlong He; Yeying Zhang; Shulan Xia
Journal:  Thorac Cancer       Date:  2020-01-10       Impact factor: 3.500

7.  TOB1-AS1 suppresses non-small cell lung cancer cell migration and invasion through a ceRNA network.

Authors:  Wen-Ji Shangguan; Hai-Tao Liu; Zu-Jun Que; Fang-Fang Qian; Ling-Shuang Liu; Jian-Hui Tian
Journal:  Exp Ther Med       Date:  2019-10-15       Impact factor: 2.447

8.  LINC01410 accelerated the invasion and proliferation of osteosarcoma by sponging miR-3128.

Authors:  Quanxiao Xu; Limin He; Lei Ma; Lin Fan; Lihua Yan; Xulin Zhao; Yuanyuan Li
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

9.  LncRNA ROR1-AS1 accelerates osteosarcoma invasion and proliferation through modulating miR-504.

Authors:  Xiangkun Wu; Lihua Yan; Yongxi Liu; Lilin Shang
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

10.  HOXC13-AS Induced Extracellular Matrix Loss via Targeting miR-497-5p/ADAMTS5 in Intervertebral Disc.

Authors:  Wanli Jing; Wei Liu
Journal:  Front Mol Biosci       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.